DIAMOND
21 Dec 2020
Trial Summary
This study aims to find out if the combination of trastuzumab (anti-HER2 therapy) with durvalumab (PD-L1 inhibitor) and tremelimumab (CTLA4 inhibitor) will reactivate anti-tumour immune response and improve clinical outcomes in trastuzumab-resistant, advanced HER2-positive breast cancer.
Acronym:
DIAMOND
ACTRN/NCT /ethics:
ACTRN12617001325392
Scientific title:
BCT 1703 (DIAmOND): Patients with HER2-positive breast cancer that have progressed on prior trastuzumab therapy will be treated with a combination of tremelimumab and durvalumab, in combination with trastuzumab, to evaluate the efficacy of the combination
Sponsor / Cooperative group:
Breast Cancer Trials
Trial & Patient Characteristics
| Cancer Type | Breast |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2018-11-01 |
| Anticipated End Date | 2020-11-30 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Hannah Adelson |
| Hannah.adelson@sa.gov.au | |
| Phone | 08 8206 4835 |
| Principal Investigator | Dr Sina Vatandoust |
| Recruitment Status | Recruiting |